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Background: While weight gain following breast cancer is considered common, results supporting these findings
are dated. This work describes changes in body weight following breast cancer over 72 months, compares weight
with normative data and explores whether weight changes over time are associated with personal, diagnostic,
treatment or behavioral characteristics.
Methods: A population-based sample of 287 Australian women diagnosed with early-stage invasive breast cancer was
assessed prospectively at six, 12, 18 and 72 months post-surgery. Weight was clinically measured and linear mixed models
were used to explore associations between weight and participant characteristics (collected via self-administered
questionnaire). Those with BMI changes of one or more units were considered to have experienced clinically significant
changes in weight.
Results: More than half (57%) of participants were overweight or obese at 6 months post-surgery, and by 72 months
post-surgery 68% of women were overweight or obese. Among those who gained more weight than age-matched
norms, clinically significant weight gain between 6 and 18 months and 6 and 72 months post-surgery was observed
in 24% and 39% of participants, respectively (median [range] weight gain: 3.9 kg [2.0-11.3 kg] and 5.2 kg [0.6-28.7],
respectively). Clinically-significant weight losses were observed in up to 24% of the sample (median [range] weight loss
between 6 and 72 months post-surgery: −6.4 kg [−1.9–24.6 kg]). More extensive lymph node removal, being treated on
the non-dominant side, receiving radiation therapy and lower physical activity levels at 6 months was associated with
higher body weights post-breast cancer (group differences >3 kg; all p < 0.05).
Conclusions: While average weight gain among breast cancer survivors in the long-term is small, subgroups of women
experience greater gains linked with adverse health and above that experienced by age-matched counterparts. Weight
change post-breast cancer is a contemporary public health issue and the integration of healthy weight education and
support into standard breast cancer care has potential to significantly improve the length and quality of cancer survivorship.
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Maintaining a healthy body weight and avoiding excessive
weight gain throughout life are common public health mes-
sages with respect to breast cancer prevention and recovery
[1,2]. Overweight or obesity following breast cancer is asso-
ciated with greater morbidity [3] and mortality [4,5]. Specif-
ically, overweight or obesity are associated with higher rates
of treatment-related sequelae, such as lymphedema, fatigue
and arthralgia [6-14], and have been associated with in-
creased risk (up to four-fold) of developing other chronic
diseases, such as type II diabetes and cardiovascular disease
[15,16]. Findings from a meta-analysis also demonstrated
that risk of breast cancer-specific and all-cause mortality
was 1.3 times higher (HR= 1.3, 95% CI: 1.2- 1.5; and 1.3:
1.2-1.5, respectively) in obese women compared with non-
obese women [17]. Weight loss, in particular for those who
enter their cancer diagnosis malnourished and underweight,
has also been linked with poor outcomes [1,18]. However, to
date, weight gain rather than weight change, with consider-
ation to gains as well as losses, has been the focus of re-
search attention for women with breast cancer.
Following a breast cancer diagnosis, weight gains ex-
ceeding five kilograms have been observed over periods
between six months [19-22] and sixty months [23] post-
surgery and have been observed in retrospective [24-26],
as well as prospective [19-23,27-35] studies. Cohorts
studied have included both pre- and post-menopausal
women [33,36], and those followed during and following
chemotherapy [19,20,22,27,28,31,34,37], radiotherapy [22,28]
and endocrine therapy [30]. While chemotherapy has
long been associated with weight gain, changes in
chemotherapy regimens (including type and duration of
administration) make its current contribution to weight
gain unclear. Other factors that have been associated
with weight gain post-breast cancer, though inconsist-
ently, include younger age, pre-menopausal status and/
or having a lower body mass index (BMI) at time of
diagnosis [38].
While earlier studies, particularly those that assessed
the effects of chemotherapy compared changes in
weight and body composition against patients who just
received localised treatment [22,28], the question of
whether these observed changes can be attributed to
aging or to breast cancer and its treatment remain. Un-
derstanding the contribution of the disease itself to
weight change is important for determining the optimal
setting (patient or public health/community), timing,
type and need for breast cancer specific advice (e.g., tak-
ing into account treatment-related sequelae) for weight
control. The purpose of this work is to describe changes
in body weight in a population-based sample of women
diagnosed with breast cancer, assessed prospectively be-
tween six and 72 months post-surgery, to compare
weight with age-matched normative data, and to explorethe personal, diagnostic, treatment and behavioral char-
acteristics associated with body weight following breast
cancer.
Methods
Ethical approval was obtained from a university human re-
search ethics committee (Queensland University of Tech-
nology, Reference Number 2179H) and access to patients
followed the standard procedures of the local cancer regis-
try. All women provided written, informed consent.
Study design and participants
The Pulling Through Study (PTS) was a prospective,
population-based, cohort study designed to track and assess
the physical and psychosocial recovery of Australian women
newly diagnosed with breast cancer. The design and sample
characteristics of the PTS) have been detailed elsewhere
[39]. Briefly, eligible participants were women, aged 20–74
years, diagnosed with a primary, invasive unilateral breast
cancer during 2002. Following informed consent, 287
women completed a self-administered questionnaire at 6, 12
and 18 months post-breast cancer diagnosis, with 74% of
these women (n = 211) also participating in a clinical assess-
ment of weight and lymphoedema at these times.
Consent was later received to follow-up the original sam-
ple of 287 women at six years (i.e., 72-months) post-
surgery. Of the 287 original participants, 11 withdrew from
the study and were therefore not recontacted. The records
of the remaining 276 women were cross-referenced with
the mortality database at the Queensland Cancer Registry
in August 2008 to determine vital status, including date
and cause of death. At the 72-month follow-up [40], 23
were deceased, 22 could not be recontacted, 36 declined
participation and the remaining 195 consented to the six-
year follow-up study.
Data collection
Clinical Assessment: Standard procedures and the same
calibrated scales were used throughout the study period.
Weight was measured to the nearest 0.1 kilogram (kg)
using Seca™ scales, with participants wearing light clothing
and no shoes, at 6-, 12-, 18- and 72-months post-surgery.
Height was assessed using a KDS™ 2m tape, and recorded
to the nearest centimeter at 6 months post-surgery. BMI
was calculated by weight (kilograms)/height2 (meters). BMI
scores of <18.5, 18.5-24.9, 25–29.9 and 30+ were catego-
rized as underweight, healthy weight, overweight and obese,
respectively.
Self-administered Questionnaire: Participants were asked
to self-report weight at 6 (self-reported pre-diagnosis weight
was also collected at this time), 12 and 18 months post-
surgery and height at 6 months post-surgery (allowing com-
parisons with other studies which do not clinically assess
weight). BMI was calculated as above. At 6 months post-
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to collect information on personal (i.e., age, education level,
income, and private health insurance), treatment (i.e., treated
side, type of surgery, lymph node removal, and status, and
type of adjuvant therapy received) and behavioral (i.e., level
of physical activity) characteristics. Physical activity was
measured using the Active Australia survey [41] with ‘seden-
tary’ defined as no activity, ‘insufficient’ defined as greater
than none, but less than 150 minutes per week, and ‘suffi-
cient’ as at least 150 minutes of physical activity a week. This
was calculated as the sum of the amount of time spent walk-
ing plus the amount of time spent in other moderate activity
plus the amount of time spent in vigorous activity (weighted
by two). Diagnostic characteristics (e.g., tumor size, type,
and grade) were abstracted from histopathology reports at
the Queensland Cancer Registry.
Normative data
Weight change observed in the PTS sample was compared
with weight change reported in the sample of the Australian
Diabetes, Obesity and Lifestyle - AusDiab study [42]. The
AusDiab study is a large national, longitudinal population-
based study involving >11,000 adults aged 25 years and
older. Baseline data collection for the AusDiab study oc-
curred during 1999–2000, with a subsequent 5-year follow-
up (during 2004–2005).
Statistical analysis
Chi-square tests were conducted to assess whether there
were any group differences on categorical variables between
the women who provided self-report and clinically-assessed
data, compared to those women who provided self-reported
data only; a statistically significant difference between groups
was defined as p < 0.05. Means and corresponding standard
deviations were calculated and reported when continuous
data were approximately normally distributed, while median
and range were presented when data were skewed or
categorical.
Proportions and 95% confidence intervals (CI) of women
in BMI categories and the proportion of women who
gained, lost and had stable weight between 6 and 18
months and 6 and 72 months post-surgery were also pre-
sented. A change of 1 BMI unit or more is associated with
adverse health events, and therefore considered a clinically
meaningful change [43]. Therefore, those with BMI
changes (between 6–18 months or 6–72 months post-
surgery) of ≥ +1 were considered to have experienced clinic-
ally significant gains in weight (categorized as ‘weight
gainers’), those with BMI changes of ≤ −1 were considered
to have experienced clinically significant losses in weight
(categorized as ‘weight losers’) and all others were catego-
rized as having ‘stable’ body weight.
Weight change between 6 and 18 months and 6 and
72 months post-surgery for each PTS participant wascompared with the mean weight change observed in a
1- and 5-year assessment period for female AusDiab
[42] participants, matched in age (10-year strata). A
PTS participant was considered to have gained more
weight than normal when their individual weight change
exceeded that of the average (mean) weight gain for their
corresponding age stratum. That is, a PTS participant
gained more weight than sex-and age-matched (within 9-
year age-strata) AusDiab participants if change in a 1-year
assessment period exceeded: 700 g (25–34 years), 500 g
(35–44 years), 380 g (45–54 years), 140 g (55–64 years), 0 g
(65–74 years). Corresponding excess weight over a 5-year
assessment period was equal to: 3500 g (25–34 years),
2500 g (35–44 years), 190 g (45–54 years), 700 g (55–64
years), 0 g (65–74 years). No normative data were available
on the 75+ age group.
In exploring the baseline (i.e., 6 months post-surgery) per-
sonal, diagnostic, treatment, and behavioral characteristics
associated with weight, and to maximize the use of all avail-
able data at each time-point and the repeated nature of the
study design, all available clinically-assessed weights for 211
women were analyzed using linear mixed models. A random
intercept was fitted for each individual and a random slope
was also fitted with respect to time. Only characteristics that
were clinically (≥3 kg, which corresponds to differences
of ≥1 BMI unit between groups) or theoretically-relevant
(hypothesis based on the literature) were included in the
final model. Interactions between time and all other charac-
teristics were also included in the model, but were subse-
quently dropped as no effect modification was observed
(p < 0.05; <3 kg difference between groups). All analyses
were performed using SPSS v18.0 (Armonk, NY, USA) and
R (Vienna, Austria). Mixed models were fitted using package
lme4 in R. Least square means were estimated from the
mixed models using the package lsmeans; statistical signifi-
cance was defined as p < 0.05.
Results
Participants
Approximately half of PTS participants were aged 55
years or older (48.4%), 75.0% underwent lumpectomy,
and the majority had axillary node resection (86.5%)
(Table 1). Three-quarters (73.7%) had infiltrating ductal
tumors, 74.0% had grade two or higher tumor grade and
40.2%, 75.7% and 57.2% received chemotherapy, radio-
therapy and/or hormone therapy, respectively. Demo-
graphic and clinical characteristics of the women who
provided self-report and clinically-assessed data were
similar to those women who provided self-reported data
only (n = 211). With the exception of number of lymph
nodes removed, those with complete data versus incom-
plete data for clinically-assessed weight had similar char-
acteristics. Further, descriptive statistics comparing
demographic and disease characteristics of women in
Table 1 Characteristics, body mass index, and weight for the Pulling Through Study clinical samplea
Characteristics N = 211 6-m PS 12-m PS 18-m PS 72-m PS
N = 211 N = 185 N = 191 N = 166
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Body mass index (kg/m2) - 27.4 (6.1) 27.3 (5.6) 27.6 (5.8) 28.2 (6.0)
Weight (kg) - 72.7 (17.2) 72.3 (15.9) 73.0 (16.1) 74.8 (17.2)
Self-reported weight (kg) - 70.5 (16.5) 71.8 (16.6) 72.3 (16.8) -
Clinically-assessed weight at
N = 211 6-m PS 12-m PS 18-m PS 72-m PS
% Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age (baseline) (age range: 30–75 years)
<45 14.6 71.6 (21.5) 72.5 (17.5) 72.4 (17.4) 75.8 (17.9)
45-54 37.0 71.9 (15.3) 71.5 (14.9) 71.7 (15.5) 72.2 (16.8)
55+ 48.4 73.6 (16.9) 72.6 (16.3) 73.8 (16.4) 75.9 (18.1)
Income, $ (baseline)
<26,000 27.3 73.6 (17.7) 73.7 (17.1) 75.0 (17.7) 77.3 (18.4)
26,000 – 51,999 27.2 74.2 (18.6) 74.3 (18.4) 73.9 (18.1) 76.1 (20.2)
>52,000/Missing 45.5 71.2 (15.7) 70.0 (13.3) 71.0 (13.8) 71.8 (15.1)
Had health insurance (overtime)
Yes 77.8 73.3 (17.4) 72.5 (15.9) 73.2 (16.4) 74.5 (17.6)
Never/Missing 22.2 70.5 (15.9) 70.7 (16.2) 71.4 (15.2) 74.5 (17.8)
Physical activityb
Sedentary 13.5 83.5 (19.6) 84.3 (16.8) 83.6 (18.4) 83.3 (19.0)
Insufficient 24.5 73.5 (15.4) 72.1 (13.8) 73.0 (13.8) 73.1 (15.5)
Sufficient 62.0 70.1 (16.3) 69.5 (15.4) 70.4 (15.6) 73.1 (17.6)
Treated on dominant side
Yes 49.0 71.0 (15.2) 71.1 (14.4) 71.9 (14.1) 72.9 (15.5)
No 51.0 74.3 (18.6) 73.2 (17.3) 73.8 (18.0) 76.1 (19.4)
Surgery
Lumpectomy 75.0 73.6 (17.7) 73.0 (16.9) 73.9 (17.0) 76.5 (18.6)
Mastectomy/Other 25.0 70.0 (14.7) 69.5 (11.7) 69.5 (12.4) 68.1 (11.9)
Histological grade
Grade 1 26.0 70.7 (17.5) 70.8 (15.6) 71.9 (17.1) 73.2 (19.7)
Grade 2/3/NA 74.0 73.4 (16.9) 72.7 (16.1) 73.2 (15.8) 75.0 (16.7)
Cancer type
Infiltrating ductal 73.7 71.3 (16.3) 71.1 (15.3) 71.4 (15.4) 72.9 (17.4)
Infiltrating lobular 13.8 76.1 (19.8) 72.2 (17.5) 75.2 (18.5) 77.4 (17.9)
Other/Missing 12.5 76.8 (17.5) 77.9 (17.1) 78.5 (17.0) 81.0 (17.1)
Lymph nodes removed
None 13.5 69.6 (15.6) 72.7 (16.3) 72.4 (15.7) 77.2 (18.5)
<10 30.8 69.4 (16.6) 68.5 (15.4) 68.4 (15.3) 71.0 (17.7)
10+ 55.7 75.2 (17.3) 74.1 (15.8) 75.3 (16.3) 75.7 (17.3)
Number of positive lymph nodes
0 58.6 73.2 (18.6) 71.6 (16.3) 72.3 (16.7) 73.9 (18.1)
<10 24.7 73.2 (14.3) 73.8 (14.9) 74.3 (15.4) 75.0 (16.7)
10+ 2.7 75.9 (10.5) 72.2 (15.1) 74.1 (14.4) 67.5 (9.3)
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Missing/NA 14.0 68.9 (15.8) 71.6 (16.8) 72.4 (15.7) 77.2 (18.5)
Received chemotherapyc
Ever 40.2 74.1 (17.2) 73.3 (14.8) 74.3 (15.2) 74.2 (16.2)
Never 59.8 71.8 (17.1) 71.4 (16.7) 71.9 (16.8) 74.7 (18.5)
Received radiotherapyc
Ever 75.7 74.2 (18.2) 73.6 (16.9) 74.2 (17.0) 75.8 (18.4)
Never 24.3 68.0 (12.1) 67.4 (11.2) 68.4 (12.1) 70.3 (14.0)
Received hormone therapyc
Ever 57.2 73.2 (17.1) 72.1 (15.0) 73.0 (15.5) 74.1 (16.2)
Never 42.8 72.1 (17.2) 72.3 (17.1) 72.6 (17.1) 75.0 (19.2)
Self-report body mass indexd
Under/Normal weight (<25) 46.9 61.6 (7.7) 61.9 (7.7) 62.2 (7.9) 62.5 (9.0)
Overweight (25–29.99) 26.1 74.6 (9.8) 74.9 (10.6) 74.9 (10.5) 76.5 (12.4)
Obese (30–39.99) 12.0 92.6 (9.7) 93.2 (9.9) 94.0 (9.2) 93.9 (11.1)
Morbidly obese (40+) 3.1 118.9 (14.2) 117.8 (10.3) 110.8 (17.3) 122.8 (3.1)
Missing 11.9 79.7 (19.3) 76.2 (12.1) 77.1 (15.4) 80.1 (18.8)
aResults presented have been weighted (<50 years: 1.0; ≥50 years: 1.3) for oversampling of younger women. bLevel of physical activity defined as sedentary:
0 minutes/week; insufficient: 1–149 minutes/week; sufficient: ≥150 minutes/week. cReceived treatment anytime up to 18 months post-surgery. dSelf-reported
weight pre-breast cancer diagnosis.
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(i.e., withdrew or lost to follow-up) showed that all base-
line characteristics of excluded women were similar to
those observed in the study sample, with the exception
of private health insurance status (a higher proportion of
those who were excluded from analyses did not have pri-
vate health insurance compared with the study sample)
(data not shown). Of note, the original cohort was
shown to be representative of the wider Queensland
breast cancer population [39].
Changes in body weight
Table 1 shows clinically-assessed BMI and weight from
6 months to 72 months post-surgery and self-reported
weight from 6 to 18 months post-surgery, as well as
weight over time for patient, treatment and behavioral
characteristics. Mean BMI increase between 6 and 18
months and 6 and 72 months post-surgery was 0.2
(range: −9.1 to +4.1) and 0.5 (range: −8.0 to +10.6), re-
spectively. Between 6 and 72 months post-surgery the
median weight increase was 0.7 kg (range: −24.6
to +28.7 kg). More than half of the participants were
overweight or obese at each time point; 57% (95% CI:
49.1% to 65.2%) and 68% (95% CI: 58.9% to 76.0%) of
women were overweight or obese at 6 and 72 months
post-breast cancer, respectively. Results from bivariate
analyses suggest that those reporting lower baseline
incomes (<$52,000/year versus > $52,000/year), lower
baseline physical activity levels (insufficiently active or
sedentary versus sufficiently active), those receiving
treatment on the non-dominant side, diagnosed withcancer type other than infiltrating ductal carcinoma, having
higher number of nodes removed (10+ versus <10) and/or
receiving radiation therapy reported clinically higher body
weights, with group differences being ≥3 kgs, which is
equivalent to a ≥ +1BMI unit difference (Table 1). Of note,
clinically-assessed weight was on average (mean) 1.7 kg
(se ± 0.1) higher than self-reported weight.Weight change among PTS cohort versus normative data
Table 2 shows clinically-assessed weight gain of the PTS
sample relative to age-matched normative data. Over
half of the PTS participants (57.8% and 56.1%) gained at
least some weight (greater than 0 kgs) between 6 and 18
months and 6 and 72 months post-surgery, respectively,
with 88.8% and 79.7% of these women experiencing
greater gains than the average (mean) weight gain expe-
rienced by age-matched norms (Table 2). Clinically sig-
nificant weight gain (i.e., weight change that led to ≥ +1
unit increase in BMI) between 6 and 18 months post-
surgery was observed in 24% of participants (median
(range) weight gain: 3.9 kg (2.0 to 11.3 kg)). Between 6
and 72 months post-surgery, 39% of women experi-
enced clinically-significant weight gain, with median
weight gain being 5.2 kg (range: 0.6 to 28.7). Between 6
and 18 months, and 6 and 72 months post-surgery, 15%
and 24% of the sample experienced clinically-significant
weight losses (median (range): −4.7 kg (−2.7 to −23.2 kg)
and −6.4 kg (−1.9 to −24.6 kg), respectively). Two women
reporting the most extreme weight losses (23.2 kg and
24.6 kg) had early stage disease.
Table 2 Clinically assessed weight gain between 6 and 18 months, and 6 and 72 months, and relative to the AusDiab
[42] study according to baseline age
Age (years) 6 to 18 months post-surgery 6 to 72 months post-surgery
Gained weight >0 kg Gained weight > normsa Gained weight >0 kg Gained weight > normsb
N % Mean (kg) n % n % Mean (kg) n %
25-34 3/5 60.0 4.6 2/3 66.7 3/4 75.0 7.7 2/3 66.7
35-44 22/28 78.6 3.8 18/22 81.8 15/19 78.9 7.0 11/15 73.3
45-54 40/69 58.0 2.4 37/40 92.5 26/51 51.0 5.1 17/26 65.4
55-64 27/53 50.9 2.2 26/27 96.3 18/38 47.4 5.3 17/18 94.4
65-74 15/28 53.6 2.5 12/15 80.0 12/20 60.0 3.2 12/12 100.0
75+ 0/2 0.0 - - - 0/2 0.0 - - -
Total 107/185 57.8 2.7 95/107 88.8 74/132 56.1 5.3 59/74 79.7
aClinical weight gain relative to sex- and age-matched AusDiab weight gain (i.e., case weight change – AusDiab average rate change per year (within 9-year
age-strata)); 25–34 years > 700 g; 35–44 years > 500 g; 45–54 years > 380 g; 55–64 years > 140 g; 65–74 years > 0 g; no data available on the 75+ age group.
bClinical weight gain relative to sex- and age-matched AusDiab weight gain (i.e., case weight change – AusDiab average rate change over 5 years (within 9-year
age-strata)); 25–34 years > 3500 g; 35–44 years > 2500 g; 45–54 years > 190 g; 55–64 years > 700 g; 65–74 years > 0 g; no data available on the 75+ age group.
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Following adjustment for potential confounding (time
since surgery, age, income, cancer grade, cancer type, sur-
gery, receipt of chemotherapy, receipt of hormone ther-
apy), the relationship between higher body weight and a
number of these characteristics (specifically, treatment on
non-dominant side, higher number of lymph nodes re-
moved, receipt of radiation treatment and lower levels of
physical activity) remained clinically and statistically sig-
nificant (all p-vales <0.05, Table 3). These associations
were similar when the 6-year post-surgery data was in-
cluded in the mixed models (data not shown).
Discussion
This is the first, population-based, study of its size to assess
weight and change in body weight over a six-year period
following breast cancer and to compare weight changes
with age-matched normative data. At six-months post-
surgery, more than half of women (57%) were overweight
or obese, and by six-years post-breast cancer 68% of
women were overweight or obese; this compares to fewer
than 50% of age-matched controls [44]. While median
weight gain for all study participants over the six-year
follow-up period was less than one kilogram, measures of
central tendency can be misleading since these data also in-
clude weight losses that may result from the cachexia of ad-
vanced disease. Thus, studying individual trajectories is
important.
In this cohort, the two women reporting the most ex-
treme weight losses (23 and 24 kg) had early stage disease
and good prognosis, suggesting that extreme weight loss
was unlikely to be associated with cachexia of advanced
disease. Nonetheless, for the 15% to 24% of the sample
who lost weight, it is unclear from our data whether this
loss was intentional, or not, and if intentional whether it
resulted from weight loss strategies that are aligned withcurrent guidelines aimed at durable change (i.e., weight
loss resulting from energy restricted diets that promote a
loss of weight of between 0.5 and 1 kg per week, combined
with increased physical activity and behavior modification)
[45]. Moreover, because data on body composition were
not collected, changes in absolute levels of adiposity within
the weight loss group are unknown. This is important to
highlight, since sarcopenic changes are prevalent in this
population, especially among those who receive chemother-
apy [22,24], and as such, it is unclear from our data whether
weight losses were likely advantageous or detrimental to
overall long-term health.
Over half of the PTS participants gained weight in the
short (6 to 18 months) and longer-term (6 to 72 months)
post-surgery. Of these women, 80% gained more weight
than the average weight gain experienced by age-matched
counterparts. Further, by 18- and 72-months post-breast
cancer diagnosis, 24% and 39% of women, respectively,
gained a magnitude of weight (that is, weight gain that led
to more than one unit increase in BMI [43]) that is linked
with adverse health [43], risk of chronic disease [1,16] and
poorer survival [17,46].
Understanding characteristics associated with weight at
diagnosis and weight change post-surgery may provide
insight into the potential for identifying subgroups of
women who would benefit most from a ‘healthy weight’
program. Our results suggest that women treated on the
non-dominant side, those with more extensive axillary
lymph node dissection, those receiving radiation treat-
ment and those not engaging in sufficient levels of phys-
ical activity each week tended to be heavier post-surgery.
With the exception of physical activity, these characteris-
tics are non-modifiable, are modest confounders of the as-
sociation between physical activity and weight, and
warrant further exploration as potential effect modifiers in
future research. Nonetheless, since overweight, obesity
Table 3 Least square means for characteristics associated
with body weight following surgery for breast cancer
Characteristicsa Body weightb Mean (SD) P-value
Treated on dominant sidecd 0.03
Yes 69.3 (2.45)
No 73.9 (2.34)
Lymph nodes removedcd 0.045
None 69.4 (3.55)
<10 70.4 (2.52)
10+ 75.0 (2.16)
Received radiotherapycde 0.009
No 67.5 (2.84)
Yes 75.6 (2.35)
Physical activitybd 0.0001
Sedentary 78.4 (3.28)
Insufficiently active 71.9 (2.46)
Sufficiently active 64.4 (2.40)
Age (years)d 0.75
<45 71.6 (3.12)
45-54 69.7 (2.64)
55+ 73.5 (2.49)
Income, $d 0.53
<26,000 72.0 (2.87)
26,000-51,999 73.1 (2.73)
>52,000/Missing 69.7 (2.40)
Surgeryc 0.31
Lumpectomy 71.7 (2.43)
Mastectomy/Other 71.5 (2.81)
Histological grade 0.67
Grade 1 70.9 (2.87)
Grade 2/3/NA 72.2 (2.09)
Cancer type 0.90
Infiltrating ductal 71.9 (1.87)
Infiltrating lobular 72.8 (3.30)
Other/Missing 70.1 (3.68)
Received chemotherapye 0.17
No 70.5 (2.28)
Yes 72.7 (2.69)
Received hormone therapye 0.36
No 70.8 (2.57)
Yes 72.4 (2.26)
aBaseline characteristics: six months post-surgery. bBody weight was analyzed
as a continuous variable. cStatistical significance defined as p < 0.05. dClinical
relevance defined as >3 kg difference between groups. eReceived treatment
anytime up to 18 months post-surgery.
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sistent contemporary breast cancer survivorship issues
that challenge quality and quantity of life, the integration
of healthy weight management into standard breast cancer
care for all women appears necessary.
Our findings demonstrating that those meeting national
physical activity guidelines (i.e., at least 150 minutes of
moderate activity/week) have clinically lower body weights
than those insufficiently active or sedentary are not surpris-
ing. Evidence-based clinical recommendations for achieving
healthy weight and/or weight loss for the general popula-
tion (and also for cancer survivors) includes a multicompo-
nent approach, involving physical activity, as well as diet
and behavior modification [18]. It is acknowledged however
that more information within this specific patient popula-
tion is required to determine optimal timing of interven-
tion, sequencing of behavioral components, as well as the
need to evaluate impact of weight maintenance on breast
cancer-specific and overall health outcomes. Nonetheless,
findings from this study clearly highlight the need for
intervention.
Potential limitations of this work are that the PTS sample
was diagnosed over 10 years ago (2002) and loss to follow-
up in this cohort was greater than 20%, which threatens the
generalizability of findings [47,48]. Nonetheless, our data
contribute the most recent prospectively and clinically-
measured body weight data within the literature and our
study represents one of the few that have compared weight
change among breast cancer survivors to population-based
controls. Published literature suggests that during chemo-
therapy (first 6/12 months) weight does fluctuate [19,24,29].
Clinical weight was not collected pre-treatment, however
based on self-reported weight pre-diagnosis, body weight
did not change significantly during the treatment period. Fu-
ture studies should build in data collection periods that
might address this issue. Further, although not perfectly
matched, the follow-up period between the PTS sample
(2002–2008) and the AusDiab normative sample (1999/
2000-2004/2005) are similar, which in turn enabled inform-
ative weight comparisons with age-matched data. Import-
antly, the PTS sample has characteristics representative of
the wider breast cancer population and study design in-
volved a long follow-up period (six years post-surgery) enab-
ling short and longer-term weight change to be evaluated.
Further, previous work has reported weight changes for the
group as a whole [19,23,30,32,34]; our results show that
group means mask key findings.
Conclusion
In summary, weight at six months post-diagnosis of
breast cancer and weight change post-surgery remains a
contemporary public health issue. There is a real need
for the incorporation of weight management strategies
into breast cancer care for all women diagnosed, though
Vagenas et al. BMC Cancer  (2015) 15:28 Page 8 of 9it may be even more important for women in certain
subgroups (e.g., those participating in insufficient levels
of physical activity). In doing so, the potential for pre-
vention and/or attenuation of breast cancer treatment-
sequelae, subsequent chronic disease and improvements
in quality and quantity of life following breast cancer is
significant.
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